Stocks · News reference
Jones Trading analyst Debanjana Chatterjee maintains Trevi Therapeutics (NASDAQ:TRVI) with a Buy and raises the price target from $24 to $28.
Reference details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Oppenheimer analyst Leland Gershell maintains Trevi Therapeutics (NASDAQ:TRVI) with a Outperform and raises the price target from $24 to $25.
Read original at benzingaCantor Fitzgerald analyst Josh Schimmer maintains Trevi Therapeutics (NASDAQ:TRVI) with a Overweight and raises the price target from $25 to $30.
Read original at benzingaTrevi Therapeutics (NASDAQ:TRVI) reported quarterly losses of $(0.11) per share which met the analyst consensus estimate. This is a 22.22 percent decrease over losses of $(0.09) per share from the same period last year.
Read original at benzinga